^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GSK5733584
i
Other names: GSK5733584, HS-20089
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
GSK, Jiangsu Hansoh Pharma
Drug class:
Topoisomerase I inhibitor, B7-H4-targeted antibody-drug conjugate
Related drugs:
1m
A Study of HS-20089 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=177, Recruiting, Shanghai Hansoh Biomedical Co., Ltd | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Metastases
|
GSK5733584
1m
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer (clinicaltrials.gov)
P2, N=460, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
Enrollment open
|
GSK5733584
1m
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=1048, Not yet recruiting, Hansoh BioMedical R&D Company
New P1 trial • Metastases
|
Avastin (bevacizumab) • cisplatin • carboplatin • GSK5733584 • adebrelimab (SHR-1316)
10ms
First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors (ESMO 2023)
The patient achieving PR with the longest treatment duration of 403 days remains on treatment in 0.7 mg/kg cohort. Conclusions Based on data from the ongoing study, HS-20089 was well tolerated and showed antitumor activities in advanced solid tumors, with encouraging clinical efficacy in TNBC.
Clinical • P1 data • Metastases
|
VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
|
GSK5733584
Share via
